What should laboratories compare when evaluating KPV price Australia quotations?
A unit price printed beside a labelled fill mass is not the cost of Lys-Pro-Val. It is a commercial figure attached to a vial of lyophilised solid. The scientifically relevant comparator for any KPV price Australia quotation is cost per milligram of peptide that has been identified, purity-assessed and content-corrected on a named lot. Four line items drive that comparator and should be read before the invoice total.
First, the claimed fill mass is a gravimetric or labelled quantity of lyophilised powder. That powder is a mixture of peptide, counter-ion, residual water and related substances. Two vials labelled as the same milligram quantity can contain different masses of Lys-Pro-Val. Treating the label as peptide mass overstates how much sequence was purchased.
Second, chromatographic purity, typically HPLC area percent at a stated wavelength, describes the share of detected peak area assigned to the main component. It is not a mass fraction of peptide in the vial and does not correct for non-chromophoric salt or water. A high area-percent value with no net peptide content still leaves the buyer unable to calculate milligrams of peptide obtained.
Third, identity evidence must show that the main component is Lys-Pro-Val rather than a deletion sequence, a diastereomer, a lysine-modified analogue or another short fragment. Experimental papers treat KPV as the MSH 11-13 tripeptide (PMID:15102092; PMID:18092346). A certificate of analysis that reports a single HPLC peak without a matching mass spectrum is incomplete for procurement comparison.
Fourth, lot number, chromatogram, mass spectrum, method identifiers and net peptide content or counter-ion data allow an Australian laboratory to file the material and to re-order against the same specification. A cheaper vial without those records is not cheaper once analyst time for incoming identity testing is included. Local stock and tracked dispatch affect lead time and receipt paperwork; they do not replace analytical evidence.
How is KPV identity confirmed as the Lys-Pro-Val tripeptide on a CoA?
The designation KPV is an amino-acid code, not a catalogue brand. In single-letter notation it is K-P-V; in three-letter notation it is Lys-Pro-Val. Experimental literature identifies this sequence as the C-terminal tripeptide of α-melanocyte-stimulating hormone, commonly written MSH 11-13 (PMID:15102092). Kannengiesser and co-workers describe KPV as a melanocortin-derived tripeptide (PMID:18092346). Brzoska and co-workers treat the C-terminal motif of α-MSH-related peptides as a discrete structural element (PMID:21222263). Those citations supply sequence context only: they indicate which elemental composition and fragment ions to expect. They are not release specifications.
A research CoA should close identity with orthogonal data. Reversed-phase HPLC documents that a principal component elutes at a stated retention time under a named column, gradient, ion-pair reagent and wavelength. Electrospray ionisation mass spectrometry should return a molecular ion consistent with the theoretical monoisotopic mass of Lys-Pro-Val as free base or as the stated salt adduct. Tandem mass spectrometry that yields b- and y-ions spanning the Lys-Pro and Pro-Val bonds is the more rigorous test, because several short peptides can share similar intact masses. That pattern distinguishes KPV from deletion peptides (KV, KP, PV) and from terminally modified species.
Lysine is chemically addressable. Songok and co-workers showed that the lysine side chain of KPV can be modified by reductive glycoalkylation (PMID:29953505). Incoming lots should be inspected for unexpected mass shifts on lysine. Gatti and co-workers studied a dimeric analogue written (CKPV)2 (PMID:16413580). A CoA for research KPV must not be ambiguous between the linear tripeptide and cysteine-containing dimers. Sequence, observed m/z and fragment assignments should all point to Lys-Pro-Val. If a quotation is silent on mass-spectrometric identity, its milligram price is not comparable to a lot that includes HPLC-MS.
Which HPLC purity and related-substance results change the cost of a KPV lot?
Short peptides are chromatographically awkward. Lys-Pro-Val has limited hydrophobic surface area, so reversed-phase retention is modest and highly sensitive to ion-pair reagent, pH and organic modifier. Trifluoroacetic acid ion-pairing is common in peptide HPLC; formic acid methods are more compatible with electrospray ionisation but often change selectivity and apparent purity. A purity figure is therefore method-defined. A CoA that reports a percentage without column chemistry, gradient, wavelength and integration parameters is not a specification another laboratory can reproduce.
Related substances that matter for a tripeptide include deletion sequences, residual dipeptides from incomplete coupling, stereoisomers, and lysine side-chain adducts. The main component and a deletion peptide may co-elute on a short gradient, so diode-array peak-purity tools (purity angle versus purity threshold, or ratiogram inspection) supplement area percent. An orthogonal MS extracted-ion chromatogram is stronger, because it can show whether more than one mass contributes to the ultraviolet peak. Laboratories that omit those checks can assign a high area percent to a composite signal.
Purity interacts with quoted price in both directions. Additional preparative HPLC and narrower fraction cutting increase manufacturing cost and usually increase the Australian list figure. A lot released at a lower area percent is not automatically better value, because the buyer then pays for unidentified peak area. A very high area-percent claim without a chromatogram, system-suitability results or a related-substance table is incomplete paperwork, not proven quality.
When comparing quotations, insist on the same purity basis: HPLC area percent at a stated wavelength, with the chromatogram and any peaks above a reporting threshold identified or marked unspecified. The relevant calculation is cost per milligram of main-component peptide after purity and content correction.
How do net peptide content, counter-ion and water alter cost per milligram?
Lyophilised research peptides are rarely one hundred percent peptide by mass. After reversed-phase purification in TFA-containing mobile phases, the isolated solid is commonly a trifluoroacetate salt. Acetate salts are produced when a counter-ion exchange step is added. Each trifluoroacetate anion contributes appreciable mass relative to a short tripeptide, and more than one anion can associate with the two basic sites on lysine. Water remaining after lyophilisation adds further non-peptide mass. The labelled vial mass is therefore a composite, and a raw Australian list price divided by that label is not a peptide unit cost.
Net peptide content expresses the peptide mass fraction after correction for counter-ion and moisture. Amino-acid analysis, nitrogen determination, or a validated HPLC assay against a content-assigned reference may be used. Karl Fischer titration separately reports water. Counter-ion can be quantified by ion chromatography or by fluorine nuclear magnetic resonance where TFA is the anion. Those measurements are required if the laboratory intends to prepare solutions on a true milligram-of-peptide basis.
Price normalisation follows directly. A working expression is cost per milligram of peptide approximately equal to vial price divided by labelled mass times net peptide content as a fraction times HPLC purity as a fraction. Area percent and net peptide content are not fully independent, so they should not be stacked as penalties without knowing how each was measured. A vial that appears cheaper on list price but carries a lower net peptide content and a heavier TFA load can be more expensive per milligram of Lys-Pro-Val. Australian quotations should state salt form, net peptide content or an equivalent content assay, and water where measured. If those fields are absent, the buyer cannot complete the arithmetic, and acetate lots must not be compared with TFA lots as if they were the same solid.
How should Australian KPV quotations be documented and normalised per milligram?
Search behaviour around research peptide supply in Australia repeatedly surfaces batch testing, lot traceability, certificate-of-analysis interpretation and laboratory peptide documentation. Those queries belong on a price page because undocumented material has a hidden analytical cost. A KPV lot that cannot be traced from vial label to chromatogram to mass spectrum is not a documented research reagent, regardless of the invoice figure.
Minimum paperwork typically includes product name and sequence (Lys-Pro-Val / KPV), lot number, labelled contents, HPLC purity with method reference and chromatogram, mass-spectrometric identity with observed m/z, net peptide content or counter-ion and water, and the testing or release date. Tandem MS sequence confirmation and residual-solvent or endotoxin fields should be written into the purchase specification if a quality system requires them. Traceability means the vial lot matches the CoA, and that multi-vial orders either share one lot with one analytical package or are broken out per lot. Shared-lot supply is usually more cost-efficient per milligram because a single HPLC-MS panel covers every vial. Local stock status, tracked dispatch and the packing list belong in the procurement file as chain-of-custody records; they do not replace identity and purity data.
For each Australian quotation record labelled milligrams, salt form, HPLC purity and wavelength, chromatogram supplied (yes/no), MS identity and tandem MS (yes/no), net peptide content or counter-ion plus water, shared-lot status, documentation inclusions, and price in Australian dollars. A first-pass normalised cost is Australian dollars per milligram of peptide approximately equal to price divided by labelled milligrams times net peptide content over one hundred times purity over one hundred. Set aside quotations that lack mass-spectrometric identity, salt form or a purity method. If purity was measured in TFA/water/acetonitrile at 220 nm in one laboratory and in formic acid at 214 nm in another, do not treat the percentages as identical.
Confirm the sequence is Lys-Pro-Val. Published chemistry describes lysine-modified KPV obtained by reductive glycoalkylation (PMID:29953505) and a dimeric construct written (CKPV)2 (PMID:16413580). Experimental formulation literature has incorporated the tripeptide into self-cross-linked polymer hydrogels (PMID:34547895). Those are different catalogue items. A low list price that forces the receiving laboratory to run identity HPLC-MS from scratch is not low once instrument time is counted. Used this way, KPV price Australia becomes a specification-driven comparison. Research use only.
Order Kpv with documentation
If this guide helped you evaluate Kpv for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Kpv card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Why can two Australian KPV vials with the same labelled milligrams have different prices?
Salt form, net peptide content, the HPLC purity method, whether mass-spectrometric identity is included, related-substance reporting, and whether several vials share one lot all change how many milligrams of verified Lys-Pro-Val are in the vial and how much analytical work sits behind the certificate of analysis. Compare a content-normalised milligram cost, not the sticker figure alone.
Is HPLC area percent enough to calculate milligram cost for KPV?
No. Area percent is a chromatographic proportion of detected peak area, not a mass fraction of peptide in the lyophilised solid. Counter-ion and residual water require a separate net peptide content assay. Use identity confirmation, purity and net peptide content together before normalising an Australian quotation to a per-milligram figure.
What identity data should a research KPV certificate of analysis show?
The printed sequence should be Lys-Pro-Val, corresponding to MSH 11-13 in the experimental literature (PMID:15102092). The file should include an HPLC main peak under a stated method and a mass consistent with that tripeptide. Tandem MS covering the Lys-Pro and Pro-Val bonds is stronger evidence than a single molecular ion alone.
Should TFA and acetate KPV lots be priced as equivalent solids?
No. The counter-ion contributes mass and can affect HPLC behaviour and laboratory workflows. Quotations should name the salt form. Convert both lots to peptide mass using net peptide content before comparing Australian prices, otherwise a heavier TFA salt can look cheaper per labelled milligram while supplying less Lys-Pro-Val.
Do local Australian stock and tracked dispatch replace a CoA?
No. Local stock and tracked dispatch improve lead time and receipt paperwork. They do not replace HPLC-MS identity, purity or content data. The milligram cost is still governed by what the certificate of analysis proves about the solid in the vial. Documentation and dispatch records serve different roles in the procurement file.
Can a formulated KPV composite be compared on price with lyophilised tripeptide?
No. Polymer hydrogels and other composites are different materials and need additional assays such as polymer content and peptide loading (PMID:34547895). Price and CoA fields for free Lys-Pro-Val should not be mixed with those for a formulated matrix. Confirm the catalogue item is the unmodified tripeptide before normalising cost.
References
- PMID:15102092 — alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells — J Invest Dermatol — 2004
- PMID:18092346 — Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease — Inflamm Bowel Dis — 2008
- PMID:21222263 — Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore — Adv Exp Med Biol — 2010
- PMID:16413580 — Inhibitory effects of the peptide (CKPV)2 on endotoxin-induced host reactions — J Surg Res — 2006
- PMID:29953505 — Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue — PLoS One — 2018
- PMID:34547895 — Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats — ACS Biomater Sci Eng — 2021
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
